NCT04427670Completed
Group Intervention Study for Individuals with Dysarthria Following Stroke and Their Carers in Pakistan
Implementation and Feasibility Study of Group Intervention for Individuals with Dysarthria Following Stroke and Their Carers in Pakistan
Source: ClinicalTrials.gov · Last updated 15 Oct 2024
Brief summary (registry, in English)
Dysarthria is a common problem in Pakistan. therefore the current study aims to translate the dysarthria communication tools into urdu language for better understanding the population and the problem
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 14 Mar 2020
- Start date
- 1 Dec 2020
- Primary completion date
- 15 Nov 2021
- Lead sponsor
- Isra University
- Diseases
- Stroke
- NCT number
- NCT04427670
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From 1 Dec 2020 to the primary completion date, 15 Nov 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with diagnosis severe psychological illness
Age
- Patient with age below 40 to 70
Other
- Patient with developmental dysarthria
- Patient who come alone without any attendent
Who the study is looking for
- 40 to 70 years age ranges
- History of dysarthria previous six monthes
- Primary level of education
- Functional hearing and visual ablities -
Age in the registry: 40 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sheikh Zayed medical Complex Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.